The 14th CBC

and a Senior Researcher of the City University of Hong Kong. He received his B.S. and M.S. degrees from Shanxi Agricultural University (1979-1983) and Beijing Agricultural University (1983-1986)

and his Ph.D. degree from the University of Oxford (UK) in 1995. In 2003

he was selected as one of the "100 Talents Program" of Chinese Academy of Sciences

and in 2005 was awarded the National Outstanding Youth Fund. He was the chief scientist of the 973 Project and the leader of the "Innovative Research Group" project of the National Natural Science Foundation of China. He has published many papers in international SCI journals (including Cell

etc.). His research interests include cross-host transmission of pathogenic microorganisms

mechanisms of infection and host cellular immunity

public health policy and global health strategy.

Vice president

Party Committee Member and Academician of the Chinese Academy of SciencesZhang Yaping

President of the Senate of PakistanSadiq Sanjrani He was graduated from Islamabad National University of Science and Technology with a master's degree in international relations; and is a Former Director of the Board of Directors of Khalifa Bin Zayed Hospital in Quetta

Chief Coordinator of the Complaints Department of the Prime Minister's Office in Islamabad

Member of the Board of Directors of Sui Southern Gas Company of the Ministry of Energy (Petroleum Department)

Chairman of the Board of Directors/Human Resources Committee of the Export Processing Zone Administration of the Ministry of Industry and Production

and Coordinator of the Special Grievance Department of the Prime Minister’s Office (Balochistan Province). Currently

he is the Chairman of the Senate of Pakistan.

President of the CBC

recipient of the "Medal of the Republic"

Academician of the Chinese Academy of EngineeringZhong NanshanZhong Nanshan

Academician of the Chinese Academy of Engineering

recipient of the "Medal of the Republic"

Professor of Respiratory Medicine of Guangzhou Medical University

Chief Scientist of the national "973" Projects

former President and advisor of the Chinese Medical Association

Honorary Professor of the University of Edinburgh

Doctor of Science of the University of Birmingham

Senior Member of the Royal Colleges of Physicians (Edinburgh

London)

and HKU Centennial Distinguished Chinese Scholar

WHO COVID-19 panel member

Director of the National Clinical Research Center for Respiratory Diseases

Honorary Director of National Center for Respiratory Medicine

Director of the Guangzhou Institute of Respiratory Diseases.Academician Zhong Nanshan is a leading figure in the prevention and treatment of bronchial asthma

chronic cough

COPD and major respiratory infectious diseases in China. He has presided over the National 973 Program

863 Program

Tenth

Eleventh and Twelfth Five-Year Plans

National Natural Science Foundation of China

WHO/GOLD Committee and other major projects; and has published more than 540 SCI papers in international academic journals

including New England Journal of Medicine

Nature Medicine

Lancet

American Journal of Respiratory and Critical Care Medicine

Chest and other international authoritative journals in the field of respiratory disease research

with a total of 10

800 citations (H-index 50). In addition

he has published more than 400 papers in national journals sponsored by the Chinese Medical Association and other institutions; published more than 20 monographs

including Asthma: From Basic to Clinical

Internal Medicine (national textbook) and Respiratory Medicine; and obtained nearly 60 invention patents and more than 30 utility models.He has successively won more than 20 awards

including the Second Prize of National Science and Technology Progress

the First Prize of Science and Technology Progress Award of the Ministry of Education

the First Prize of Guangdong Science and Technology Progress; and has received dozens of honorary awards

including the Bethune Medal (2004)

Southern Guangdong Merit Award (2011)

Wu Jieping Medicine Prize (2011)

Guanghua Engineering Science and Technology Prize of CAE (2016)

Huang Danian National Teaching Team Award (2017)

Reform Pioneer (an important promoter of the construction of China's public health event emergency system)

the Most Honorable Striver of New China (2019) and the Medal of the Republic (2020).

Nobel Prize Winner in Physiology or Medicine in 2005Barry Marshall Since the discovery of Helicobacter pylori with Robin Warren in 1982

Professor Barry Marshall has been leading the research team for in-depth exploration of Helicobacter pylori. He has won many awards for his discovery of Helicobacter pylori

the most remarkable of which was the Nobel Prize in Physiology or Medicine in 2005. Over the past few years

Professor Barry Marshall's laboratory has developed and intensified non-invasive studies on the molecular epidemiology of H. pylori

most notably the rapid breath test and the detection of the pathogen from swallowed wires. Ondek

a biotechnology company of Professor Barry Marshall

which focuses on the development of delivery systems for vaccines and drug therapies using specific

genetically modified Helicobacter pylori

has successfully received funding from national and international investors in recent years.

Deputy Director and Secretary General of the Committee on Biodiversity of CAS

Director of IUCN and Chairman of the Asia Region Membership Committee

and Researcher of the Institute of Botany

CASMa Keping Ma Keping

a Researcher at the Institute of Botany

CAS and a Professor at the University of Chinese Academy of Sciences Director of IUCN and Chairman of the Asia Region Membership Committee

Deputy Director and Secretary General of the Committee on Biodiversity of CAS

Editor-in-Chief of Biodiversity and Associate Editor of Chinese Science: Life Sciences

and an Editorial Board Member of National Science Review and other journals. In recent years

he has mainly conducted research on biodiversity maintenance mechanisms

conservation biogeography and biodiversity and ecosystem function

and published more than 260 SCI papers

including those in Science

PNAS

Science Advances

Nature Ecology and Evolution

Nature Communications and other academic journals; and edited more than 20 monographs/collections. As a scientific advisor to the Chinese government delegation

he has participated in most of the conferences of the parties to the UN Convention on Biological Diversity. Topic: Biodiversity Conservation in the Next DecadeAbstract: The first phase of the 15th Conference of the Parties to the United Nations Convention on Biological Diversity (COP 15) is held in Kunming in October 2021. For China

the host of the Conference

it is both an opportunity to participate in global governance and a platform to demonstrate China's commitment and achievements in compliance. The COP 15 is of great importance

and in the second phase

it will take stock and assess the progress and problems encountered in the implementation of the 20 targets of the 2011-2020 Global Biodiversity Conservation Strategic Plan; meanwhile

it will consider the adoption of the Global Biodiversity Conservation Strategic Framework for the next decade. For the development of the conservation framework for the next decade

China should play an active role; and should

moreover

well summarize the experience and cases that China has achieved in biodiversity conservation under the guidance of ecological civilization ideology

and provide successful cases and technical methods that other parties

especially developing country parties

can learn from on how to coordinate conservation and development. In the past

strict protection of threatened species and ecosystems was mainly carried out

and although this is the most basic work

it is far from enough. Therefore

attention should also be paid to the restoration of ecosystems

and when they are restored

wildlife can gradually recover. In addition

the implementation of sustainable production and sustainable consumption is a very important initiative and is known as transformative change. Biodiversity is lost because of the threats posed by human production and consumption

and will continue to be lost if production and consumption are not controlled. Therefore

the new conservation concept requires all of society to act and cooperate together to protect biodiversity.

Academician of the American Academy of Engineering

CTO of Bioscience of Lawrence Berkeley National Laboratory

CEO of the United Bioenergy Research InstituteJay Keasling He is an international pioneer in the industrialization of synthetic biology and an academician of the American Academy of Engineering

and is currently the CTO of Bioscience of Lawrence Berkeley National Laboratory

the CEO of the United Research Institute of bioenergy

the Director of the Synthetic Biology Engineering Research Center of the University of California

Berkeley

and an outstanding Chair Professor of Hubbard Howe. Jay Keasling has won the "International Eni Award"

"Heinz Award"

"International Metabolic Engineering Award" and other important awards

and has also been rated as "technology pioneer"

"scientist of the year" and "innovator of the year" by the world economic forum

exploration

economist and other magazines. He creatively designed and constructed microorganisms for the production of antimalarial drug artemisinin

which changed the traditional method of extracting artemisinin from traditional Chinese medicine. In addition

he

as the initiator

has successively established American listed companies Amyris

LS9 and Lygos

which are recognized as part of the most successful models of the industrialization and commercialization of synthetic biology.

Academician of Chinese Academy of SciencesHe Fuchu Cell biology

geneticist

academician of Chinese Academy of Sciences

Director of the Science and Technology Committee of the Academy of Military Sciences

Chairman of the National Center for Protein Science (Beijing)

Director of the State Key Laboratory of Proteomics. He is mainly engaged in research in proteomics

precision medicine and systems biology. He has discovered 7% new human genes

discovered a series of molecular evolutionary laws

and revealed a series of disease susceptibility genes in Chinese population. He was the first to develop and transfer for production the genetically engineered hematopoietic factor in China

the first in the world to propose the scientific goal and technical route of the human proteome project

and advocated and led the first international human tissue organ proteome project "Liver Proteome Project". He led the implementation of the "Chinese Proteome Project" and completed the proteomic analysis of the top ten common tumors in China

pioneering the independent molecular typing of tumors by proteomics. In addition

he has found that reprogramming of cholesterol metabolism is an important mechanism in the development of hepatocellular carcinoma

and was the first to propose and practice the new paradigm of "proteomics-driven precision medicine".

Director

Tianjin Institute of Industrial Biotechnology

Chinese Academy of SciencesMa Yanhe Ma Yanhe is currently the Deputy Director of the Standing Committee of the 17th People's Congress of Tianjin

member of the Standing Committee of the Central Committee of the Chinese Peasants and Workers Democratic Party and Chairman of the Tianjin Municipal Committee of the Party

and Director of the Tianjin Institute of Industrial Biotechnology of the Chinese Academy of Sciences. He has long been engaged in the research in biotechnology and has undertaken many important scientific and technological tasks in this field in China. He was the chief scientist of a major project in the synthetic biology in the National 973 Program and expert in the 863 Program

promoted the technological innovation and industrialization implementation of multiple industrial biomanufacturing products

led the teams to develop several new industrial enzymes and industrial strains

promoting the major development of China's oligosaccharide industry

breaking the international monopoly of key industrial strains and pushing forward the green transformation of chemical synthesis processes. He has published more than 380 SCI-indexed papers in Science

Nature Communications

Angew Chem Int Ed and other journals

one monograph in English

and has 350 invention patents granted or pending at home and abroad. He was awarded the second prize of the National Technical Invention Award and four first prizes at provincial and ministerial level.

President and CEO of United ImagingXue Min Dr. Xue Min

President of United Imaging. She has more than 30 years of experience in industrial technology research and industrialization

and received a doctorate in biomedical engineering from Case Western Reserve University and Cleveland Clinic in the United States

and is known as one of the earliest scholars engaged in magnetic resonance research in China. In 1998

Xue Min founded Shenzhen Maidite Instrument Co.

Ltd. and served as President

leading the team to successfully develop China's first 1.5T superconducting magnetic resonance system.Since 2011

under the leadership of Xue Min

the Company has completed the design

R&D and manufacturing of 109 high-end medical imaging and radiotherapy products and core components in just 10 years

including the total body PET-CT (2m PET-CT)

"space-time integration" ultra-clear TOF PET / MR

3.0T exploration magnetic resonance

integrated CT-linac and a number of products pioneered in the world and China

which have rapidly developed itself into an industry-leading medical innovation enterprise.